Novo Nordisk Pushes Beyond Wegovy: OpenAI Deal, Zenagamtide Trials, and a UAE Hub Reshape the Story

Despite a 33% stock drop, Novo Nordisk accelerates AI integration with OpenAI, launches five Phase 3 obesity trials, and builds a UAE logistics hub to counter US pricing pressure.

Novo Nordisk’s stock has shed more than a third of its value over the past year, but the Danish drugmaker is not standing still. This week alone, the company unveiled an artificial-intelligence pact with OpenAI, kicked off five new late-stage trials for its experimental obesity drug Zenagamtide, and confirmed plans for a distribution hub in the United Arab Emirates that will serve up to 70 countries. Each move targets a different weak spot — R&D speed, pipeline breadth, and global supply chain — as the group scrambles to offset mounting pricing pressure in the United States.

The partnership with OpenAI is the most structurally significant. Novo intends to deploy the US firm’s AI capabilities across its entire value chain, from early drug discovery to logistics, with full integration targeted by the end of 2026. Pilot programmes are already running in research, manufacturing and sales. The company already works with Nvidia and uses the Gefion supercomputer for drug development, but OpenAI brings a different level of scale and competition — Sanofi, Moderna and Eli Lilly have all signed similar deals as the race for AI expertise in pharma intensifies.

On the clinical front, Novo has launched five new Phase?3 studies for Zenagamtide, the next-generation obesity candidate. The trials — dubbed AMAZE?3 through 6 plus AMAZE?12 — are investigating the drug in obesity combined with sleep apnoea and knee osteoarthritis, and a separate arm is testing whether Zenagamtide can sustain long-term weight loss. Both conditions are common comorbidities of excess weight, and a win here would significantly bolster Novo’s metabolic portfolio.

Meanwhile, the oral version of Wegovy, the only approved peptide-based weight-loss pill, has already been used by more than a million patients since its launch in January. Novo raised its full-year revenue and operating profit guidance in the first quarter of 2026 on the back of that pill. But it remains locked in a fierce battle with Eli Lilly, which has eroded Novo’s first-mover advantage. The company is betting on the oral formulation and next-generation assets to reclaim lost ground.

Operationally, the new logistics centre in the UAE is designed to support more than 2.6?million patients across the Gulf, Africa and Central Asia. It will be one of three global distribution nodes, linking production sites in Europe, Asia and the Americas with fast-growing demand regions. The move underlines a growing divergence in Novo’s top line: in the first quarter, international sales rose 6?percent on a currency-adjusted basis, while US adjusted revenues fell 11?percent as lower realised prices outweighed volume growth. Group adjusted revenues — stripping out the reversal of a 340B provision — declined 4?percent, even as adjusted obesity-drug revenues jumped 22?percent.

The stock closed at €38.74 on Friday, up 1.25?percent on the day and 16?percent over the past month. Yet the year-to-date loss stands at 13.29?percent, and the one-year decline is 35.79?percent. The 200-day moving average of €42.19 sits about 8?percent above the current price, suggesting the recovery is technically fragile. Novo’s ongoing buyback programme, worth up to 15?billion Danish kroner over twelve months from February, has repurchased roughly 16?million B?shares at an average price of 260.62?kroner, for a total of around 4.2?billion kroner.

Analyst sentiment remains split. S&P Global’s consensus of 14 analysts sees a target of about $46.72 with a buy rating, while a broader poll of 23 estimates is more neutral. Kepler Cheuvreux rates the stock a hold with a target of 290 Danish kroner, and Bernstein SocGen Group is outright bearish at 200 kroner. For 2026, Novo still expects adjusted revenues and adjusted operating profit to decline between 4?percent and 12?percent, currency-adjusted and excluding the 340B effect — a sign that the pricing headwinds are far from over.

Technically, the shares need to hold above €39.37 to sustain the recent bounce, with €42.19 as the next meaningful resistance. Investors will get a fresh read on the trajectory when half-year results land on 5 August. By then, the market will judge whether the OpenAI deal, the Zenagamtide pipeline and the UAE hub can together tip the balance in Novo’s favour.